Does Abilify Cause False-Positive Drug Screens?
Yes, Abilify (aripiprazole) can cause false-positive results for amphetamines on urine drug screening immunoassays, though this is not mentioned in the FDA label and appears to be an uncommon but documented phenomenon.
Evidence for False-Positive Amphetamine Screens
The most direct evidence comes from case reports demonstrating that aripiprazole specifically causes false-positive amphetamine results on immunoassay-based urine drug screens:
Documented cases in both children and adults: Multiple case reports confirm false-positive amphetamine screens with aripiprazole use. In pediatric accidental ingestions (15-45 mg doses), positive amphetamine screens occurred that were subsequently negative on confirmatory GC-MS testing 1.
Adult therapeutic dosing: A 40-year-old woman on therapeutic aripiprazole (15-30 mg/day) showed false-positive amphetamine screens with a documented relationship between aripiprazole dose, plasma concentration, and amphetamine values over time 2.
Confirmatory testing is negative: In all reported cases, gas chromatography-mass spectrometry (GC-MS) confirmation testing was negative for amphetamines, proving these were false positives 1.
Clinical Context and Mechanism
Why this occurs: Immunoassay-based screening tests are susceptible to cross-reactivity due to antibody recognition of structurally similar compounds 3. While the exact mechanism for aripiprazole's cross-reactivity with amphetamine immunoassays is not fully elucidated, this phenomenon has been documented across multiple independent reports 4, 5.
Frequency: This appears to be an uncommon occurrence, as the FDA label for Abilify does not list false-positive drug screens among adverse reactions 6. However, the literature review identifies aripiprazole among psychotropic medications known to cause false-positive results 4.
Critical Clinical Recommendations
When encountering a positive amphetamine screen in a patient taking aripiprazole:
Do not assume illicit drug use - Document the patient's complete medication history, including aripiprazole dose and timing 3
Order confirmatory testing immediately - Request GC-MS or LC-MS/MS analysis, which will definitively rule out true amphetamine use 3, 1, 7
Avoid premature clinical decisions - Do not alter psychiatric treatment, initiate substance abuse interventions, or make legal/employment determinations based solely on the screening result 2, 1
Consider the clinical picture - If the patient categorically denies amphetamine use and the clinical presentation is inconsistent with stimulant intoxication, false-positive is more likely 4
Important Caveats
Screening vs. confirmatory testing: Initial immunoassay screens are presumptive only and require confirmation 3, 5, 8. The guideline explicitly states that "confirmatory tests are highly unlikely to yield false-positive results" 3.
Cannot distinguish therapeutic from illicit use: Even confirmatory testing cannot differentiate between prescribed amphetamines (e.g., for ADHD) and illicit use - it only confirms presence or absence 3.
Legal and therapeutic implications: False-positive results can lead to unnecessary treatment, monitoring, legal consequences, and damage to the therapeutic relationship 2, 1.
The bottom line: Always obtain confirmatory GC-MS testing before making any clinical, legal, or therapeutic decisions based on a positive amphetamine screen in patients taking aripiprazole. The screening immunoassay alone is insufficient evidence of illicit drug use 3, 1, 7.